204 related articles for article (PubMed ID: 30777101)
1. Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8
Kalimutho M; Sinha D; Mittal D; Srihari S; Nanayakkara D; Shafique S; Raninga P; Nag P; Parsons K; Khanna KK
J Exp Clin Cancer Res; 2019 Feb; 38(1):85. PubMed ID: 30777101
[TBL] [Abstract][Full Text] [Related]
2. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
3. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
4. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
[TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
6. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
[TBL] [Abstract][Full Text] [Related]
7. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
[TBL] [Abstract][Full Text] [Related]
8. miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.
D'Ippolito E; Plantamura I; Bongiovanni L; Casalini P; Baroni S; Piovan C; Orlandi R; Gualeni AV; Gloghini A; Rossini A; Cresta S; Tessari A; De Braud F; Di Leva G; Tripodo C; Iorio MV
Cancer Res; 2016 Sep; 76(18):5562-72. PubMed ID: 27402080
[TBL] [Abstract][Full Text] [Related]
9. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
10. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
11. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
12. PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.
Plantamura I; Casalini P; Dugnani E; Sasso M; D'Ippolito E; Tortoreto M; Cacciatore M; Guarnotta C; Ghirelli C; Barajon I; Bianchi F; Triulzi T; Agresti R; Balsari A; Campiglio M; Tripodo C; Iorio MV; Tagliabue E
Mol Oncol; 2014 Jul; 8(5):968-81. PubMed ID: 24747080
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.
Camorani S; Hill BS; Fontanella R; Greco A; Gramanzini M; Auletta L; Gargiulo S; Albanese S; Lucarelli E; Cerchia L; Zannetti A
Theranostics; 2017; 7(14):3595-3607. PubMed ID: 28912898
[TBL] [Abstract][Full Text] [Related]
15. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S; Teo ZL; Caramia F; Savas P; Mintoff CP; Virassamy B; Henderson MA; Luen SJ; Mansour M; Kershaw MH; Trapani JA; Neeson PJ; Salgado R; McArthur GA; Balko JM; Beavis PA; Darcy PK; Loi S
Nat Commun; 2017 Sep; 8(1):606. PubMed ID: 28928458
[TBL] [Abstract][Full Text] [Related]
16. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitor Efficacy Depends on CD8
Pantelidou C; Sonzogni O; De Oliveria Taveira M; Mehta AK; Kothari A; Wang D; Visal T; Li MK; Pinto J; Castrillon JA; Cheney EM; Bouwman P; Jonkers J; Rottenberg S; Guerriero JL; Wulf GM; Shapiro GI
Cancer Discov; 2019 Jun; 9(6):722-737. PubMed ID: 31015319
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
19. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
20. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
